drugset / Trial / NCT00366457
Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer
Phase 2
Completed
32 enrolled
Massachusetts General Hospital
Beth Israel Deaconess Medical Center · collabDana-Farber Cancer Institute · collabGenentech, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to learn whether or not the combination of gemcitabine, bevacizumab and erlotinib works in treating patients with advanced or metastatic pancreatic cancer. Bevacizumab is a new anti-cancer drug. It is an antibody that works to slow or stop cell growth in cancerous tumors by decreasing the blood supply to the tumors. It is approved by the FDA for the treatment of colorectal cancer but is still considered investigational for treating pancreatic cancer.
Timeline
- Start
- 2006-08
- Primary completion
- 2008-08
- Completion
- 2011-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Erlotinib | Small molecule | — | Oral |
| Subject | Gemcitabine | Small molecule | — | Intravenous |